Kairos Pharma, Ltd. (KAPA)
| Market Cap | 13.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.60M |
| Shares Out | 16.69M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,963 |
| Open | 0.8548 |
| Previous Close | 0.8549 |
| Day's Range | 0.8209 - 0.8548 |
| 52-Week Range | 0.7500 - 4.0000 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 8.33 (+913.88%) |
| Earnings Date | May 23, 2025 |
About KAPA
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-ĸβ pathway, a can... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for KAPA stock is "Strong Buy." The 12-month stock price forecast is $8.33, which is an increase of 913.88% from the latest price.
News
Kairos Pharma, Ltd. Announces Participation in the D.
Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D.
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO)...
Kairos Pharma Ltd. Provides Letter to Stockholders
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.: To our valued stock...
Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib af...
Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company (the “Company'”), announces the completion of the safety lead-in of its Phase 2 clin...
Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and announces participation in...
Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a peer-reviewed publication highlighting a potentially significant breakt...
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that the company presented preclinical data on its investigational compou...
Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sinai Medical Center, C...
Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppressio...
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the plenary session of the joint...
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of t...
Kairos Pharma Provides Business Update and Outlook into 2025
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppressio...
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, and Neil Bhowmick, C...
Kairos Pharma: Potential To Remove Resistance With Established Drugs
ENV-105 targets CD105 proteins to restore sensitivity in cancer cells, enhancing the efficacy of existing therapies like ERLEADA and TAGRISSO. Kairos Pharma's ENV-105 aims to overcome resistance in CR...
Kairos Pharma to Participate in The Microcap Conference in January 2025
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, ...
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppressio...
IBN Initiates Coverage of Kairos Pharma Ltd.
LOS ANGELES, Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, has...
Kairos Pharma to Present at the LD Micro Main Event XVII
LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, wil...
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, wil...
Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Serv...
U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost
Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition, respectively. Seven IPOs and three SPACs submitted initial filings. Eight...
Kairos Pharma Closing of $6.2 Million Initial Public Offering
LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics ...
Kairos Pharma Prices $6.2 Million Initial Public Offering
Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA” Company anticipates commencement of trading on the NYSE American effective Septemb...
Kairos Pharma to sell 1.55 million shares in IPO at $4 each
Kairos Pharma plans to sell about 1.55 million shares in its initial public offering at $4 per share.